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This  report  summarizes  the  discussion,  conclusions,  and  points  of  consensus  of the  IWGT  Working  Group
on Quantitative  Approaches  to Genetic  Toxicology  Risk  Assessment  (QWG)  based on  a meeting  in  Foz
do  Iguac¸ u,  Brazil  October  31–November  2, 2013.  Topics  addressed  included  (1)  the  need  for  quantita-
tive  dose–response  analysis,  (2)  methods  to  analyze  exposure–response  relationships  &  derive point  of
departure  (PoD)  metrics,  (3)  points  of  departure  (PoD)  and  mechanistic  threshold  considerations,  (4)
approaches  to deﬁne  exposure-related  risks,  (5)  empirical  relationships  between  genetic  damage  (muta-
tion) and  cancer,  and  (6)  extrapolations  across  test  systems  and  species.  This  report  discusses  the ﬁrst
three  of these  topics  and  a companion  report  discusses  the  latter  three.  The  working  group  critically  exam-
ined  methods  for determining  point  of departure  metrics  (PoDs)  that  could  be used to estimate  low-dose
risk  of genetic  damage  and  from  which  extrapolation  to acceptable  exposure  levels  could be  made  using
appropriate  mode  of  action  information  and  uncertainty  factors.  These  included  benchmark  doses  (BMDs)
derived  from  ﬁtting  families  of exponential  models,  the  No Observed  Genotoxic  Effect Level  (NOGEL),Please cite this article in press as: J.T. MacGregor, et al., IWGT report on quantitative approaches to genotoxicity risk assessment I.
Methods and metrics for deﬁning exposure–response relationships and points of departure (PoDs), Mutat. Res.: Genet. Toxicol. Environ.
Mutagen. (2014), http://dx.doi.org/10.1016/j.mrgentox.2014.09.011
and  “threshold”  or breakpoint  dose  (BPD)  levels  derived  from  bilinear  models  when  mechanistic  data
supported  this  approach.  The  QWG  recognizes  that  scientiﬁc  evidence  suggests  that  thresholds  below
which  genotoxic  effects  do not  occur likely  exist for  both  DNA-reactive  and  DNA-nonreactive  substances,
but  notes  that  small  increments  of  the  spontaneous  level  cannot  be unequivocally  excluded  either  by
 The opinions and recommendations expressed in this publication are those of the authors, and do not necessarily reﬂect those of the institutions with which they may
e  afﬁliated.
∗ Corresponding author. Tel.: +1 410 991 9948; fax: +1 239 947 7447.
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E-mail addresses: jtmacgregor@earthlink.net (J.T. MacGregor), paul.white@hc-sc.gc.ca (P.A. White).
ttp://dx.doi.org/10.1016/j.mrgentox.2014.09.011
383-5718/© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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experimental  measurement  or by  mathematical  modeling.  Therefore,  rather  than  debating  the  theoretical
possibility  of  such  low-dose  effects,  emphasis  should  be placed  on determination  of  PoDs  from  which
acceptable  exposure  levels  can  be determined  by  extrapolation  using  available  mechanistic  information
and appropriate  uncertainty  factors.  This  approach  places  the  focus  on minimization  of  the  genotoxic
risk,  which  protects  against  the risk  of  the development  of diseases  resulting  from  the  genetic  damage.
Based  on analysis  of  the  strengths  and  weaknesses  of each  method,  the  QWG  concluded  that  the  order
of  preference  of PoD  metrics  is  the statistical  lower  bound  on the  BMD  >  the  NOGEL  >  a statistical  lower
bound  on the  BPD. A  companion  report  discusses  the use  of  these  metrics  in genotoxicity  risk  assessment,
including  scaling  and  uncertainty  factors  to  be  considered  when  extrapolating  below  the  PoD  and/or
across  test  systems  and  to the  human.
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. Introduction
The International Workshops on Genotoxicity Testing (IWGT)
ring together experts in the ﬁeld of genetic toxicology approx-
mately every four years to develop consensus recommendations
n genetic toxicology testing methods and testing strategies. Begin-
ing in 2002 a series of working groups addressed different
spects of hazard identiﬁcation/characterization and risk assess-
ent strategies [1,2]. At the 2009 meeting in Basel, Switzerland,
he working group on follow-up testing of agents that elicited
ositive responses in in vivo assays [3] agreed on “the need for
 consensus about the most appropriate mathematical models
nd statistical analyses for deﬁning non-linear dose–responses and
xposure levels associated with acceptable risk”. Those points were
ecently further discussed by a Working Group on Quantitative
pproaches to Genetic Toxicology Risk Assessment (QWG) orga-
ized as part of the October 31–November 2, 2013 meeting of the
WGT in Foz do Iguac¸ u, Brazil. This QWG  addressed the following
opics:
. The need for quantitative dose–response analysis of genetic tox-
icology data
. The existence and appropriate evaluation of threshold responses
. Methods to analyze exposure–response relationships & derive
points of departure (PoDs) for extrapolation to low-dose expo-
sure levels
. Approaches to deﬁne exposure-related risks
. Empirical relationships between genetic damage (mutation) and
cancer
. Extrapolation across test systems and species.
This report is the ﬁrst of two that summarize the discussions and
ecommendations of the QWG. It focuses on issues 1–3 listed above,
rovides the background and rationale for quantitative approaches
n genotoxicity hazard identiﬁcation, and addresses methods and
etrics for deﬁning dose–response relationships and determining
oDs for extrapolation to low-dose exposure levels. A second report
ill consider issues 4–6 and address considerations for extrapola-
ion below PoDs, uncertainty factors in extrapolation from PoDs,
xtrapolation across test systems and species, and overall consid-
rations on the use of quantitative approaches in genotoxicity risk
ssessment.
. Background and objectives: the need for quantitative
ose–response analysis of genetic toxicology data
Regulatory genetic toxicology testing was ﬁrst introduced in
orth America, Europe and Japan in the 1970s and early 1980sPlease cite this article in press as: J.T. MacGregor, et al., IWGT repor
Methods and metrics for deﬁning exposure–response relationships an
Mutagen. (2014), http://dx.doi.org/10.1016/j.mrgentox.2014.09.011
4–9]. These regulations and recommendations emphasized the use
f a speciﬁed hazard screening battery consisting of in vitro tests
or gene mutation and chromosomal damage and an in vivo test for
hromosomal damage in hematopoietic tissue. These reports andhed  by  Elsevier  B.V.  This is  an  open  access  article  under  the  CC  BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
guidelines also recognized the need for quantitative in vivo data to
establish quantitative estimates of human risk. In its ﬁrst compre-
hensive guideline on the application of genetic testing procedures,
the U.S. Department of Health Education, and Welfare (DHEW) Sub-
committee on Environmental Mutagenesis (1974–1977) stated the
following [10]:
• “It is not sufﬁcient to merely identify substances which may  pose
a genetic hazard to the human population.”
• “. . .it is necessary to obtain quantitative data from relevant ani-
mal  model systems from which extrapolations to humans can be
made to predict virtually safe or tolerable levels of exposure”.
However, this early recommendation for a quantitative analy-
sis of in vivo risk was  eclipsed by the initial enthusiasm generated
by the ﬁnding of an apparent close concordance between in vitro
mutation assays and in vivo cancer outcomes, initiated in large part
by the analysis of Ames and McCann [11,12]. Within a few years
a perception developed that mutagens and carcinogens were rel-
atively rare and that hazard screening could identify them so that
human exposure could be limited or eliminated (i.e., by applica-
tion of the precautionary principle). At that time, cancer became
the main health consequence of concern in many regulatory agen-
cies, including the U.S. Food and Drug Administration (FDA); this
was a change from the original DHEW report that emphasized
the importance of heritable germ cell damage. Moreover, database
analyses suggested that potency measured using in vitro tests was
not a reliable indicator of in vivo potency [13,14] and the rel-
ative insensitivity of the in vivo tests [15,16] discouraged their
use outside of a battery of tests designed for hazard identiﬁca-
tion. As a result, regulatory testing and decision-making have until
recently been based largely on qualitative outcomes of in vitro
and/or in vivo genotoxicity tests, leading to dichotomous classiﬁ-
cation of an agent as genotoxic/mutagenic/clastogenic/aneugenic,
or not, with cancer as the principal genetic disease of con-
cern.
More recently it has become recognized that qualitative out-
comes of in vitro genotoxicity tests do not adequately correspond
to the outcomes of rodent carcinogenicity bioassays or with in vivo
genotoxicity. Among the key publications demonstrating the short-
comings of over-reliance on screening tests for genotoxic hazards
is Snyder and Green’s report [17] that ∼25% of pharmaceuticals in
the 1999 Physicians’ Desk Reference (PDR) were positive in in vitro
mammalian cell tests (after exclusion of chemotherapy agents)
even though their use is considered safe. Moreover, Sofuni et al.
[18] report that 38% of 1049 new chemical substances evaluated
under the Chemical Substances Control Law in Japan were positive
in a mammalian cell chromosomal aberration assay. Further, thet on quantitative approaches to genotoxicity risk assessment I.
d points of departure (PoDs), Mutat. Res.: Genet. Toxicol. Environ.
extensive summary by Kirkland et al. [19], which concluded that
in vitro cytogenetic tests exhibit high sensitivity but low speciﬁcity
when compared with in vivo rodent cancer test outcomes (i.e.,
with many positive outcomes for agents that were negative in
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odent cancer bioassays), demonstrates that in vitro assays often
how effects that are not reproduced in in vivo studies. Some
imitations of the Kirkland analysis have been pointed out [20],
nd more recent surveys suggest that current methods reduce
he fraction of positive results [21,22]. Nonetheless, it is clear
hat cellular exposures attained in in vitro assays often greatly
xceed those achievable in vivo and potentially lead to toxicity
nd cellular disturbances that cause genetic damage that would
ot occur under conditions more reﬂective of actual in vivo expo-
ures. Because qualitative classiﬁcation as positive or negative
or a particular endpoint is often insufﬁcient for risk assessment,
egulatory agencies have already begun to mandate more com-
rehensive consideration of the relevance of in vitro positive
ndings, including differences in exposures that might inﬂuence
n vivo outcomes. Therefore an overall weight of evidence (WoE)
pproach that takes into account genotoxicity data in the context
f all other relevant information is currently being emphasized
hen evaluating genotoxic hazard and risk. Examples include the
ollowing:
FDA guidance on integration of genetic toxicity data during
review of preclinical drug safety studies [23], which emphasizes
consideration of the overall weight of evidence
the ICHS2 revision that places increased weight on in vivo out-
comes [24]
for genotoxic impurities, the EMA  and draft ICH and FDA guid-
ances that recognize both thresholds of toxicological concern
(TTC) for genotoxic substances and exposure limits associated
with negligible risk based on magnitude and duration of exposure
[25–27]
Several consortia and working groups have also highlighted
he need to include quantitative information (i.e., dose–response
nformation) in the weight of evidence approach, and are cur-
ently engaged in the development of guidelines for quantitative
pproaches that will improve the assessment of potential risks from
xposures to genotoxic agents. These include the IWGT (see, e.g.,
3]), the Health and Environmental Sciences Institute of the Inter-
ational Life Sciences Institute [28–30]), and other groups (e.g.,
31]).
There was a clear consensus of the QWG  that increased uti-
ization of quantitative information, especially in vivo information,
ould improve the assessment of risks posed by exposure to
enotoxic agents. However, there are currently no internationally-
ccepted guidelines for the quantitative analyses of genetic toxicity
ose–response functions or for the use of quantitative potency
etrics in risk assessment and regulatory decision-making. There-
ore a principal objective of the QWG  was the development of
ecommendations for appropriate methodologies to describe geno-
oxicity exposure–response relationships and to derive points of
eparture (PoD) metrics. An additional objective was to develop
ecommendations for the utilization of such metrics for the assess-
ent of human risk associated with exposure to genotoxic agents.
In early discussions, the QWG  agreed that it is not practical
o conduct comprehensive quantitative risk assessments for all
xisting chemicals, due to the overwhelming cost and resources
hat would be needed to obtain the necessary data and to con-
uct such analyses. Therefore, there is a need for a tiered approach
hat depends to a large extent on the level of concern estab-
ished by hazard screening, the anticipated level of exposure,
nd evaluation of other available data. Such strategies have been
escribed elsewhere and were not a focus of the QWG  discuss-Please cite this article in press as: J.T. MacGregor, et al., IWGT repor
Methods and metrics for deﬁning exposure–response relationships an
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ons. Rather, the QWG  focused on quantitative approaches to be
sed when the degree of exposure and potential hazard warranted
 quantitative analysis to support risk characterization and risk
anagement. PRESS
search xxx (2014) xxx–xxx 3
The risk assessment and risk characterization process for geno-
toxic agents has been described previously by a working group
sponsored jointly by the United Nations Environmental Program
(UNEP) and the International Commission for Protection Against
Environmental Mutagens and Carcinogens (ICPEMC) [32,33], which
was based on the framework for risk assessment previously deﬁned
by a National Academy of Sciences working group [34]. This process
is illustrated in the ﬁgure below, redrawn, with permission, from
the 1994 ICPEMC/UNEP publication [35] (Fig. 1).
The QWG  focused on the dose(exposure)–response stage of
this process, including the use of quantitative data from lab-
oratory investigations of genotoxicity and related endpoints to
estimate acceptable human exposures; i.e.,  deﬁnition of exposure
response relationships, determination of and extrapolation from
points of departure, integration of exposure information with the
exposure–response relationships to estimate responses at expo-
sure levels relevant to those in humans, and integration of the
available information with uncertainty factors to extrapolate to
human health risk. Due to the diversity of products and environ-
mental exposure scenarios that may  require evaluation, it is not
possible or desirable to recommend one set of criteria for risk man-
agement that applies to all situations. Therefore the QWG  efforts
focused on the identiﬁcation of key elements and factors that
should be used in a general framework for risk assessment that is
applicable in most situations. Risk management is expected to be
implemented by regulatory agency professionals and risk managers
responsible for speciﬁc product classes and environmental expo-
sure situations, and will incorporate speciﬁc criteria and acceptable
risk levels applicable to those particular situations and exposure
scenarios.
Examples of speciﬁc regulatory criteria and testing require-
ments that have already been deﬁned for some product classes and
environmental exposure situations include:
• FDA food additive levels of concern based on a combination of
chemical structure class and exposure, [36].
• Thresholds of regulation: food exposures below which testing
requirements are reduced [37] or eliminated [38].
• The exposure-related allowance for genotoxic impurities during
drug development speciﬁed in the EMA, FDA, and ICH guidance
documents [25–27], based on carcinogenicity potency data (i.e.,
10−5 or 10−6 increased risk of cancer).
• The Canadian Department of National Health and Welfare
(CDHNW, now known as Health Canada) testing requirements
for environmental contaminants, drugs, and foods, including cat-
egorization by level of concern [6,39].
2.1. The existence and evaluation of threshold responses
An important topic discussed by the QWG  was  the existence of
thresholds for genotoxic effects. There is general consensus that
genotoxic agents acting by some non-DNA-reactive mechanisms
are expected to exhibit a threshold exposure level (i.e.,  dose or
concentration) below which no biological effect is expected. Exam-
ples of these mechanisms include mitotic spindle disturbance,
nucleotide pool imbalance, glutathione depletion, and inhibition
of DNA synthesis [28,40–42]. Additional examples and references
are given in the QWG  companion manuscript on the use of quanti-
tative data in genetic toxicity risk assessment [43]). DNA-reactive
genotoxicants, in contrast, have often been considered to have
a ﬁnite risk at any dose (e.g., [44]). However, regardless of the
mechanism it is impossible to determine experimentally at lowt on quantitative approaches to genotoxicity risk assessment I.
d points of departure (PoDs), Mutat. Res.: Genet. Toxicol. Environ.
dose ranges whether or not there is a small incremental risk
within the normal distribution of the ever-present spontaneous
background. Further, a small increase in a unique deleterious
genetic alteration that is not present in the normal spontaneous
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(Fig. 1. Elements of risk ass
ackground would be very difﬁcult to identify or rule out. More-
ver, any set of dose–response data – no matter how extensive
 will be mathematically consistent with both threshold and
ow-dose linear responses [45]. Since neither experimentation
or mathematical analysis can deﬁnitively exclude small geno-
oxic effects within the normal background range, the QWG
oncluded that it is not productive to argue about the exist-
nce of thresholds for mutagenic and clastogenic agents. Rather,
mphasis should be placed on determination of PoDs from which
cceptable exposure levels can be determined by extrapolation
sing available mechanistic information and appropriate uncer-
ainty factors. This approach places the focus on minimization
f the genotoxic risk, which is expected to protect against the
isk of the development of diseases that could result from the
enetic damage. Such an approach has been recommended by the
ealth Protection Branch of the Canadian Department of National
ealth and Welfare (now known as Health Canada) [6,39,46],
hich recognized “genotoxic activity as a potential hazard for
dverse human health effects, and, accordingly, that genotox-
city is a bona ﬁde toxicological endpoint”. Thus, in the late
980s and early 1990s regulatory agencies such as Health Canada
ere already recognizing the need for a uniform methodology
or the quantitative toxicological evaluation of substances that
nhance the risk of adverse health effects via induction of genetic
amage.
.2. Methods to analyze exposure–response relationships &
erive point of departure (PoD) metrics
The discussion that follows focuses on appropriate methods
or deﬁning exposure–response relationships for genetic toxicity
nd establishing PoDs from which extrapolation can be made to
etermine acceptable exposure limits. When deﬁning approaches
o derive appropriate PoDs, one should ﬁrst identify desirable
haracteristics of each approach and metric. These desirable char-
cteristics include:
(i) Well deﬁned & robust:  the method and associated PoD metricPlease cite this article in press as: J.T. MacGregor, et al., IWGT repor
Methods and metrics for deﬁning exposure–response relationships an
Mutagen. (2014), http://dx.doi.org/10.1016/j.mrgentox.2014.09.011
should be applicable to a wide variety of dose–response data,
including sparse data
ii) Conservative: the method should employ approaches
that account for data uncertainty and attempt to avoident and risk management.
underestimating the actual risk by deﬁning the PoD as a
statistical lower bound
iii) Transparent: the assumptions required to derive the PoD should
be clearly articulated
iv) Ease of calculation:  the procedure for analysis and PoD deter-
mination should be straightforward, using publicly available
methods and/or software
(v) Interpretable biological meaning: the result should be linked to
undesirable physiologic effects that are in turn related to human
disease. The PoD on these results should be an index of risk in
the lower measurable range.
Three main approaches have been used to date to derive PoDs
for human health risk assessment (HHRA).
(i) The No Observed Genotoxic Effect Level (NOGEL), which is the
no-observed effect level (NOEL) for a genotoxicity endpoint, is
deﬁned as the highest tested dose for which no statistically
signiﬁcant increase in the incidence of the genotoxic effect
is observed relative to an appropriate untreated or vehicle-
treated control, and below which there are no statistically
signiﬁcant increases in the genotoxic effect. The NOEL and
NOAEL (no observed adverse effect level) are widely used in
regulatory settings (e.g., [36,47]), and the NOGEL is directly
analogous because genetic damage is generally considered to
be an adverse effect.
(ii) The benchmark dose (BMD), or benchmark concentration
(BMC), is a dose or concentration that results in a deﬁned
change (benchmark response or BMR) in the level of an adverse
response. Different benchmark approaches are generally used
with quantal data (in which a subject is classiﬁed as affected or
not affected, such as cancer occurrence) and continuous data
(in which a subject’s response can be essentially any value in a
range, such as mutation or micronucleus frequency when the
subject’s response is considered to be a continuous variable). A
statistical lower bound on the BMD  (BMDL) can be used as the
PoD [29,30,48–50]. The BMD  approach has been used by many
agencies for determining PoDs for health-based guidance (e.g.,
[51–53]).t on quantitative approaches to genotoxicity risk assessment I.
d points of departure (PoDs), Mutat. Res.: Genet. Toxicol. Environ.
When applied to quantal data the benchmark dose can be
deﬁned as the dose that results in an additional fraction (BMR)
of subjects that have the adverse response. If P(x) represents
the probability of responding at a dose of x, then P(0) is the
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Fig. 2. Dose–response modeling results for HPRT gene mutations induced by MMS  in vitro in AHH-1 cells. (a) Bilinear dose–response modeling used to deﬁne the BPD and
BPDL,  (b) BMD dose–response modeling used to deﬁne the BMD10 and BMDL10. The three parameters, including a NOGEL derived using a 1-sided Dunnett’s test, a BPDL, and
a  BMDL10, are shown in both graphs for comparison. For (a), the solid line shows the best ﬁt of the bilinear function, and the dotted line shows the bilinear model with the
B
RPDL  as the lower 95% conﬁdence limit of the breakpoint dose [64].
eproduced, with permission, from Gollapudi et al. [29].
background response rate. Accordingly, P(x)–P(0) represents
the additional fraction responding at a dose of x, and the BMD
is deﬁned as the dose that satisﬁes
P(BMD) − P(0) = BMR  (1)
where BMR  is a number between 0 and 1 selected in advance.
If, for example, BMR  is selected as BMR  = 0.1, the corresponding
BMD  is often denoted by BMD10 as it is the dose that results
in an additional 10% of subjects observed to be affected. To
calculate a BMD  one must posit a mathematical form for the
probability of response, P(x). Thus, P(x) will involve statisti-
cal parameters whose values are estimated by ﬁtting P(x) to
data. Statistical procedures can be used for evaluating how well
the selected dose response ﬁts the data and for calculating the
BMDL (lower statistical bound on the BMD).
When applied to continuous data the benchmark dose can
be deﬁned as the dose that causes a speciﬁed average change
(BMR) in a response in the direction that is considered adverse
(either increasing or decreasing) relative to that response in
unexposed subjects. If the posited mathematical form F(x) rep-
resents the average level of response when exposed to dose
x, then F(x)–F(0) represents the average change in response
caused by dose x. If an increase in the normal background
response is considered adverse then the BMD is deﬁned as the
dose that satisﬁes
F(BMD) − F(0)
F(0)
= BMR  (2)
If, instead a decrease in the normal background response
is considered adverse, then the numerator is replaced by
F(0) − F(BMD). Alternatively, the BMR  for continuous data can
be deﬁned as a change in response relative to the normal vari-
ation as measured by , the standard deviation, in unexposed
subjects,
F(BMD) − F(0)

= BMR  (3)
[54–56]. The BMD  so-deﬁned is sometimes denoted byPlease cite this article in press as: J.T. MacGregor, et al., IWGT repor
Methods and metrics for deﬁning exposure–response relationships an
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BMD1SD (the change in response corresponding to one
standard deviation). A variation of this approach, called
the “hybrid approach”, involves deﬁning the most extreme
responses (e.g., the most extreme 5%) among unexposedsubjects to be “affected”. This allows the BMD from continu-
ous data to have the same interpretation as those from quantal
data (i.e., both deﬁned by Eq. (1) (see [54,55,57–59] for more
details). Otherwise, BMDs deﬁned from Eqs. (1), (2), or (3) may
not be comparable even if based on the same numerical value
of BMR. A majority of members of the QWG  expressed a pref-
erence for deﬁning BMD  from continuous genotoxic data using
Eq. (2) rather than Eq. (3).
The BMDL, a lower statistical conﬁdence bound on the BMD,
can be a suitable PoD for either continuous or quantal geno-
toxicity data. The BMDL satisﬁes the desirable characteristic of
being conservative by incorporating a quantitative estimate of
one of the types of model uncertainty.
When using the BMD  approach, the functions, P(x) or F(x),
used to model the incidence or continuous response as a func-
tion of dose, x, must be speciﬁed, and the criteria used to select
the mathematical form of P(x) or F(x) need to be appropriately
deﬁned. For BMD  analysis of continuous data, it is often rea-
sonable to assume a log-normal distribution for the response at
a ﬁxed dose, where the variation (log-normal standard devia-
tion) does not depend upon dose. If the variation does depend
upon dose, it may  be necessary to model that variation as a
function of dose (i.e., model  as a function of dose,  = (x)).
A useful measure of uncertainty when using the BMD  method
is the BMDU/BMDL ratio (BMDU is the statistical upper limit
on the BMD). A large BMDU/BMDL ratio suggests that the
data may  not be suitable for deﬁning a sufﬁciently reliable
PoD [60].
In the QWG  analyses (Fig. 2), which involved continuous
responses, a BMR  of 10% was  used, corresponding to an
increase equal to 10% of the background (negative control)
level. It should be noted that for quantal data, such as can-
cer incidence data, a BMR  of 10% in absolute incidence rate
is often selected to calculate a PoD. It should be emphasized
that while both approaches generate a PoD that is referred
to as a “BMD10”, they are substantially different because the
continuous response analysis, which is generally applied to
genotoxicity data when the response of a subject is consideredt on quantitative approaches to genotoxicity risk assessment I.
d points of departure (PoDs), Mutat. Res.: Genet. Toxicol. Environ.
to be a continuous variable, is based on a BMR  of a speciﬁed
percentage increase (often 10%) of the spontaneous incidence,
whereas the quantal analysis of cancer data is generally based
on an absolute increase of 10% tumor incidence.
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Table 1
Characteristics and recommended data needs of methods considered by the QWG.
BMD  NOGEL Bilinear
Recommended minimum data 3 doses plus control 3 doses plus control* ≥5 doses (including the negative control)
Amount  data used Whole data set used Only data in one dose group is used Whole data set used
Known effect size? Yes (BMR) No No
Covariate analysis possible? Yes No No
Estimate heavily dependent on experimental conditions? No Yes Yes
Conﬁdence limits Yes No Yes
(
i
S
I
s
a
c
[
T
A* Generally required to approximate NOGEL unless a limit dose is negative.
Software packages designed for performing the calculations
needed for BMD  analysis include PROAST [61]) and the EPA’s
BMDS software [62]). Both are available for download and
use without cost: (http://www.rivm.nl/en/Documents and
publications/Scientiﬁc/Models/PROAST; http://www.epa.gov/
ncea/bmds/dwnldu.html).
iii) The threshold or breakpoint dose lower conﬁdence bound
(BPDL), determined using a bi-linear model, has also been used
in human health risk assessment [63]. In this approach, a bi-
linear dose response function is ﬁt to the data: it is composed
of two intersecting straight lines with the low-dose line having
a zero slope. Examples of such models are those described by
Lutz and Lutz [64] and Muggeo [65]. A statistical lower bound
on the point of intersection of the two lines is considered an
estimate of the threshold dose (highest dose with no change
in response, or BPD) and can be used as a PoD. This method
assumes the existence of a threshold dose, and consequently
should not be used unless there is general agreement that the
available mechanistic information supports this assumption.
This approach is equivalent to a BMD  approach that uses a spe-
ciﬁc dose response model (i.e., a bi-linear model) and a BMR  = 0.
Bilinear modeling [29,64–66] can be used to reject a linear dose
response relationship across the entire dose range. Addition-
ally, when statistical assumptions are met  and the analysis is
supported by mechanistic information, bilinear modeling can
be used to accept a dose–response relationship with zero slope
below the estimated threshold or BreakPoint Dose (BPD).
The Quantitative Analysis Working Group of the Genetic Tox-
cology Technical Committee of the Health and Environmental
ciences Institute (part of the International Life Sciences Institute:
LSI-HESI GTTC QAW) guidance document and R packages containPlease cite this article in press as: J.T. MacGregor, et al., IWGT repor
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tatistical software for ﬁtting the bilinear model [30,67]. Note that
 log-transformation of the doses before ﬁtting the bi-linear model
an cause a linear dose response to appear to have a threshold (e.g.,
45]) and consequently can cause bi-linear modeling to predict a
able 2
dvantages and disadvantages of methods considered by the QWG.
Method BMD  NOGE
Measurement Benchmark dose – dose associated with a speciﬁc
benchmark response (BMR)
Highe
statist
respon
Advantages -  Sparse data tends to yield a lower PoD - Is ea
-  Uses data efﬁciently and takes account of the shape of the
dose response. (Fits a model to data)
- Does
respon
-  Currently used by many regulatory agencies
Disadvantages -  Requires consensus on appropriate biologically relevant
benchmark response (BMR)
Sparse
yield a
-  Continuous and quantal data are modeled differently Statist
must bthreshold dose, when, in fact, one does not exist. Consequently,
the QWG  does not recommend log-transforming the experimental
doses when applying the bi-linear model.
2.3. Comparison of the different methods to analyze
exposure–response relationships & derive points of departure
Each of the above three approaches for analysis of genetic tox-
icity data in risk assessment was  considered by the QWG, and the
characteristics, data requirements, advantages and limitations of
each are summarized in Tables 1 and 2. In considering the merits
and limitations of each approach, the QWG  took into account the
extensive scientiﬁc and practical regulatory experience of the QWG
members with these methods, the analyses and recommendations
of the Quantitative Working Group of the HESI Genetic Toxico-
logy Testing Committee that have been summarized by Gollapudi
et al. [29]) and Johnson et al. [30], and additional de novo analyses
conducted by QWG  members. The nature of the analyses and the
metrics evaluated are illustrated by Figure 2 from Gollapudi et al.
[29], which presents a summary of the quantitative analysis of the
dose-response for hprt gene mutations induced by MMS  in vitro in
AHH-1 cells.
This ﬁgure illustrates the ﬁtted dose–response curves and
shows the PoD metrics derived by applying the BMD  and bi-linear
approaches. In this case, the bilinear model of Lutz and Lutz [64] was
employed, although the QWG  noted that the R-based segmented
analysis described by Muggeo [65] has a number of advantages that
make it preferable for bilinear modeling [30].
Fig. 3, which is derived from the results presented by Johnson
et al. [30], presents the calculated PoDs from selected examples of
data from various in vitro and in vivo assays for gene mutation and
micronucleus induction in animals and mammalian cells exposedt on quantitative approaches to genotoxicity risk assessment I.
d points of departure (PoDs), Mutat. Res.: Genet. Toxicol. Environ.
to ENU or MNU.
The data summarized in Figs. 2 and 3 exemplify the general ﬁnd-
ings with a large number of data sets, including those reported by
Gollapudi et al. [29] and Johnson et al. [30], those reported in the
L Breakpoint dose determination using a bi-linear model
st dose with no
ically signiﬁcant
se
Estimate of threshold
sy to apply - Sparse data tends to yield a lower PoD
 not require dose
se modeling
- May  be appropriate when mechanistic information
supports threshold expectation
 data tends to
 higher PoD
- Based on speciﬁc assumption that data is described by
one line of zero slope and another of ﬁnite slope
ical assumptions
e met
- is highly model dependent (other models will ﬁt just as
well but predict very different PoD)
-  is not robust (PoD often cannot be determined for sparse
data sets)
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Fig. 3. Comparison of PoD metrics for ENU or MNU  response in different assays and endpoints. (a) In vitro assays for gene mutation and micronucleus induction. (b) In vivo
assays  for gene mutation in different tissues and micronucleus induction in bone marrow. ND, breakpoint was indeterminate. The PoD metrics presented are the BMDL10,
t
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Nhe  BMD1SD, the NOGEL, and the BPDL.
ompanion report of the IWGT QWG  [43], and with the experience
f QWG  members over the course of their careers.
Noteworthy conclusions and comments, based on critical com-
arisons of the methods and metrics, include:
1) BMD  modeling almost always yields a good ﬁt to the data,
2) The BMDL10 (the lower conﬁdence limit on the benchmark
response rate of 10% over background), derived from the best
ﬁtting model, generally provided a conservative (lower) value
relative to the NOGEL and the BPDL,
3) The BMDL10, though recently employed in studies reported in
the literature, is an arbitrary choice of minimal response based
on the presumption that a BMR  of 10% of the spontaneous rate is
a minimal increase in response that is close enough to the range
of observable responses to be estimated with reasonable accu-
racy. Since most genotoxicity assays currently employed do not
have the statistical sensitivity to detect less than a doubling
of the spontaneous rate (i.e., a 100% increase in the sponta-
neous rate), the choice of a BMR  of 10% results in a PoD that is
approximately 1/10 (or less for certain assays) of the detectable
NOGEL,
4) The BMDL approach is very ﬂexible, can be readily applied to
a wide range of datasets, is minimally affected by dose spac-
ing, and requires only three treatment levels. Dose spacing is
more critical for determination of the NOGEL and BPD, and BPD
analysis requires approximately six treatment groups,
5) The BMDL10 and BMDL1SD values are essentially always lower
than the NOGEL and are therefore more conservative.
Although a large number of data sets from different types
f assays were evaluated, rigorous comparisons were limited to
 relatively small sample of structural classes of genotoxicantsPlease cite this article in press as: J.T. MacGregor, et al., IWGT repor
Methods and metrics for deﬁning exposure–response relationships an
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i.e.,  mainly monofunctional alkylating agents, aromatic amines,
nd polycyclic aromatic hydrocarbons). It is therefore desirable
o extend these analyses to additional structurally diverse agents.
onetheless, the QWG  considered that a number of conclusionscould be drawn. Below we  discuss each approach and provide
consensus statements and guidance regarding their use and appli-
cation.
3. Conclusions and points of consensus
• It is well-accepted that biological understanding of the mecha-
nism of action of some non-DNA-reactive agents supports the
expectation of a threshold exposure below which there is no
effect.
• Although biological understanding of protective mechanisms and
DNA repair capacity often supports the expectation of a no-
effect threshold for some DNA-reactive mutagens, it is generally
not possible to conclusively establish whether or not a small
incremental risk exists within the normal range of spontaneous
damage solely by experimental measurement of DNA damage
(due to existing background and experimental error) or math-
ematical analysis of the dose–response data.
• Since the presence of an absolute no-effect threshold cannot
be conclusively demonstrated, emphasis should be placed on
the determination of PoDs from which limits of exposure asso-
ciated with an acceptable risk level can be determined. The
weight of evidence regarding the mechanism of induction of the
damage, extent of repair and other protective cellular defenses,
and the available exposure, pharmacokinetic, and metabolism
data can then be used to determine if more or less conservative
assumptions, uncertainty factors or extrapolation are appropriate
in a particular case.
• The rank order of QWG  preference for the method of deriving the
PoD lies in the order of BMD  > NOGEL > the statistical lower bound
of the breakpoint dose (BPDL) derived from bilinear modeling.t on quantitative approaches to genotoxicity risk assessment I.
d points of departure (PoDs), Mutat. Res.: Genet. Toxicol. Environ.
The BMDL is robust and conservative and thus is recommended
for general use as the PoD.
• The BMD  approach was considered to be the preferred approach
for dose(exposure)–response analysis and PoD derivation for
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genotoxicity data because: (1) dose–response analysis can be per-
formed on studies with minimal data, (2) it uses the entire data
set to derive a BMD  estimate, (3) the size of the effect is deﬁned,
(4) covariate analysis can be performed, (5) within limits, the
PoD value is not adversely affected by experimental design and
dose selection (e.g., NOGELs from two different experiments can
vary signiﬁcantly due to differences in dose spacing and statistical
sensitivity), (6) conﬁdence limits can be derived. In addition, the
BMDL10 was generally the most conservative of the PoD estimates
considered by the QWG.
There was agreement that BMD  analysis is suitable for deﬁn-
ing PoDs for genetic toxicology data for both discrete (quantal)
and continuous responses. Based on experience to date with
continuous data, benchmarks deﬁned as a speciﬁed increase rel-
ative to background appear to have the greatest acceptance with
respect to the analysis of genetic toxicology data [60], although
other deﬁnitions such as the hybrid approach have frequently
been used for other types of endpoints [51,57].
There was agreement that the NOGEL can be a suitable PoD for
genetic toxicity dose–response data. Appropriate statistical crite-
ria for deriving and applying NOGEL values are necessary, as is the
case for all approaches. The ILSI-HESI GTTC QAW standard oper-
ating procedure [68] and R package [67] are suitable for NOGEL
analyses using Dunnett’s, Dunn’s or Dunnett’s T3 tests depend-
ing on the distributional characteristics of the data [30]. A trend
test can also be used for deﬁning a NOGEL, especially for stud-
ies with large numbers of dose groups; however software and
methods for performing these tests are not yet included in the R
package and SOP. Basing a NOGEL on a stepwise trend test that
uses all the data may  increase the statistical power of the NOGEL
determination.
Although there was general agreement among the QWG  that
the bi-linear model could be used to determine a PoD when
mechanistic data supports the existence of a threshold dose, sig-
niﬁcant drawbacks of the BPD method were recognized. First, the
assumption that the true model is composed of two intersect-
ing straight lines is not appropriate unless there is mechanistic
information that supports it. The PoD (i.e., BPD, or threshold dose
estimate) obtained from this approach is highly dependent upon
the validity of this assumption. For example, Crump [45] showed
that there will always be a dose–response model that ﬁts the data
as well as the bi-linear and that predicts a zero threshold dose
(i.e., that has a positive slope at all doses in the low-dose range).
This underlies the reason for selecting a BMR  in the benchmark
approach that is greater than zero – this ensures that the BMD
is always greater than zero (and therefore useful as a PoD). Sec-
ondly, bi-linear modeling cannot be used to determine a PoD in
all cases, even in all cases where the data are from an experi-
ment where a threshold is deemed to be plausible. This is a result
of the fairly frequent ﬁnding that the statistical lower bound on
the threshold estimate will include zero and consequently be
unsuitable as a PoD. Furthermore, the QWG  considered the bilin-
ear model to be more dependent on factors such as the number
and spacing of doses and statistical power within dose groups
than other approaches. Therefore, the QWG  considered the use
of the bilinear model to be too restricted. In contrast, the BMD
approach is generally applicable irrespective of whether or not
there is a threshold dose, and also has other advantages described
above.
In general, the best ﬁtting dose–response model consistent with
the biological mechanistic information for a given data set should
be used to analyze the data within the observable dose range andPlease cite this article in press as: J.T. MacGregor, et al., IWGT repor
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to derive a PoD.
In all cases, there is a need for high quality data, with transparent
characterization of the uncertainties around the risk estimation
approach. PRESS
search xxx (2014) xxx–xxx
Tables 1 and 2 summarize some of the recommended data needs
and characteristics of the three approaches for computing PoDs, and
the major advantages and disadvantages of each.
In summary, the consensus among the QWG  participants was
that determination of the PoD by the BMD  method is favored when-
ever it is supported by the data; otherwise the NOGEL method may
be used. The QWG  was divided regarding the use of bi-linear mod-
eling for determining a PoD. Most QWG  members agreed that the
bi-linear model could be used for determining a PoD when mecha-
nistic data support the existence of a threshold dose, while at least
one panel member disagreed, citing the disadvantages of the bi-
linear method discussed above. Thus, each of the 3 approaches can
be used to deﬁne a PoD, but the preference of the QWG  lies in the
order: BMD  > NOGEL > bilinear.
Considerations when extrapolating dose–response data from
PoDs to determine low-dose human risks are summarized in the
second publication in this series [43]. These factors should be deter-
mined on a case-by-case basis by regulatory authorities and risk
managers within their areas of responsibility, but the QWG  pro-
vides a general framework of factors to consider and approaches for
incorporating them into regulatory decision-making. Uncertain-
ties include those in extrapolating below the PoD, in extrapolating
across test systems and from laboratory results to human effects,
and human inter-individual variability and genetic susceptibil-
ity. These uncertainties determine the magnitude of safety and
uncertainty factors that must be applied to a PoD to determine an
estimate of acceptable exposure.
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ppendix 1. List of abbreviations and deﬁnitions1
BMC  (Benchmark Concentration): The concentration of a sub-
stance that is associated with a speciﬁed low incidence of response
of a biological effect, generally in the range of 1–10%.
BMCL (Benchmark Concentration Low): A lower one-sided conﬁ-
dence limit on the BMC.
BMD  (Benchmark Dose; for quantal data): A dose or exposure of
a substance associated with a speciﬁed absolute increase in the
incidence of a biological response, generally in the range of 1–10%.
BMD  (Benchmark Dose; for continuous data): A dose or exposure
that produces a predetermined percentage change in response rate
of an adverse effect relative to the existing background incidence,
generally in the range of 1–10% increase in the background.
BMD10 (Benchmark Dose10): Benchmark Dose associated with a
10% response adjusted for (for quantal data) or relative to (for
continuous data) background.
BMD1SD: Benchmark dose associated with an increase relative to
background of 1SD of the mean background value.
BMDL (Benchmark Dose Lower Limit): A statistical lower conﬁ-
dence limit on the dose or concentration at the BMD.
BMDL10 (Benchmark Dose Lower Limit10): The lower conﬁdence
limit of a benchmark response rate of 10% (for quantal data) or 10%
increase in the background frequency (for continuous data).
BMR (Benchmark Response): The response, generally expressed as
in excess of background, at which a benchmark dose or concentra-
tion is desired (see Benchmark Dose, Benchmark Concentration).
BPD (Breakpoint Dose): The dose at which the slope changes from
zero (horizontal) to positive, with its standard error forming the
conﬁdence bounds [30].
BPDL: Lower conﬁdence limit on the breakpoint dose.
CHMP: Committee for Medicinal Products for Human Use (CHMP),
a committee of the European Medicines Agency.
DHEW: U. S. Department of Health, Education, and Welfare.
EFSA: European Food Safety Authority.
EMA: European Medicines Agency.
EMS: Ethyl Methanesulfonate.
ENU: N-Nitroso-N-methylurea, Ethyl Nitrosourea.
FDA: U.S. Food and Drug Administration.
HHRA: Human Health Risk Assessment.
ICH: International Conference on Harmonisation of Technical
Requirements for Registration of Pharmaceuticals for Human Use.
ICH S2(R1): ICH guideline S2 (R1) on genotoxicity testing and data
interpretation for pharmaceuticals intended for human use.
ILSI-HESI GTTC QAW: International Life Sciences Institute, HealthPlease cite this article in press as: J.T. MacGregor, et al., IWGT repor
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and Environmental Sciences Institute, Genetic Toxicology Testing
Committee, Quantitative Assessment Working Group.
IWGT: International Workshops on Genotoxicity Testing.
1 See also: http://www.epa.gov/ncea/bmds/bmds training/appendices/glossary.
tm, Benchmark Dose Software (BMDS), Appendix C: Glossary of Terms, APPENDIX
,  GLOSSARY OF TERMS; http://ofmpub.epa.gov/sor internet/registry/termreg/
earchandretrieve/glossariesandkeywordlists/search.do, Vocabulary Catalog List
etail – Integrated Risk Information System (IRIS) Glossary, Terms & Acronyms;
ollapudi et al., EMM,  54, 8–18, 2013.
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LOGEL (Lowest Observed Genotoxic Effect Level) The lowest tested
dose for which a statistically signiﬁcant increase in the incidence
of the genotoxic effect is observed, relative to an appropriate back-
ground control incidence.
MMS:  Methyl Methanesulfonate.
MN:  micronucleus.
MNU: N-Nitroso-N-methylurea, Methyl Nitrosourea.
NOAEL (No Observed Adverse Effect Level): The highest tested
dose for which no statistically signiﬁcant increase in the incidence
of an adverse effect is observed and below which no statistically
signiﬁcant response occurs relative to an appropriate untreated
control.
NOGEL (No Observed Genotoxic Effect Level): The highest tested
dose for which no statistically signiﬁcant increase in the incidence
of the genotoxic effect is observed, and below which no statistically
signiﬁcant response occurs, relative to an appropriate untreated
control (i.e., background).
PCE: polychromatic erythrocyte.
PoD (Point of Departure): The point on a dose–response curve
established from experimental data from which extrapolation
below the PoD may  be employed, in conjunction with the appli-
cation of uncertainty factors, for low-dose risk assessment and
determination of an acceptable exposure level, or reference dose.
A PoD can be a data point or an estimated point that is derived
from observed dose–response data. This point can be the lower
bound on dose for an estimated incidence or a change in response
level from a dose–response model (BMD), or a NOAEL or LOAEL for
an observed incidence, or change in level of response.
QWG: IWGT Working Group on Quantitative Approaches to
Genetic Toxicology Risk Assessment.
Td: Threshold Effect Level is the dose at which the slope changes
from zero (horizontal) to positive when using the bilinear hockey
stick model [29].
Td CI: The conﬁdence limits on the Td.
TdL CI: The lower conﬁdence limit on the Td.
U.S. EPA: United States Environmental Protection Agency.
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